3/1/2022 8:36:27 AM
Gilead Gets Complete Response Letter From FDA For Investigational Lenacapavir Due To Vial Compatability Issues
2/11/2022 8:07:27 AM
Gilead Says Remdesivir Retains Antiviral Activity Against Omicron, Delta And Other SARS-CoV-2 Variants In Studies
2/1/2022 4:40:36 PM
Gilead Sciences Q4 EPS $0.30 Vs. $1.23 Year Ago
2/1/2022 4:26:29 PM
Gilead Sciences Inc. (GILD) Declares $ 0.73 Dividend for Q1 22, Record Date 3/15/2022
1/31/2022 9:04:03 AM
Gilead : FDA Approves New Label Update For CAR T-Cell Therapy Yescarta
1/25/2022 8:19:54 PM
Gilead Announces Partial Clinical Hold For Studies Evaluating Magrolimab In Combination With Azacitidine
1/10/2022 8:42:36 AM
Gilead, Merck To Evaluate Trodelvy In Combination With KEYTRUDA In First-Line Metastatic Non-Small Cell Lung Cancer